Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
Identifieur interne : 000F21 ( Main/Exploration ); précédent : 000F20; suivant : 000F22Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
Auteurs : Brian E. Davies [États-Unis]Source :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2010.
Abstract
Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children ≥1 year and adults of all ages may decrease the severity and duration of the symptoms of infection, while prophylactic dosing can prevent their onset. Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg twice daily. This predictable profile means that oseltamivir is suitable for use in diverse patient populations, which may include young children and elderly patients, various ethnic groups and those with renal or hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients with co-morbid conditions who are likely to be receiving concomitant medications.
Url:
DOI: 10.1093/jac/dkq015
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001543
- to stream Istex, to step Curation: 001543
- to stream Istex, to step Checkpoint: 000188
- to stream Main, to step Merge: 000F29
- to stream Main, to step Curation: 000F21
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations</title><author wicri:is="90%"><name sortKey="Davies, Brian E" sort="Davies, Brian E" uniqKey="Davies B" first="Brian E." last="Davies">Brian E. Davies</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:81AE9C6C106E8206463503E64196239F7BDFA0B9</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1093/jac/dkq015</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-4DQXP250-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001543</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001543</idno><idno type="wicri:Area/Istex/Curation">001543</idno><idno type="wicri:Area/Istex/Checkpoint">000188</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000188</idno><idno type="wicri:doubleKey">0305-7453:2010:Davies B:pharmacokinetics:of:oseltamivir</idno><idno type="wicri:Area/Main/Merge">000F29</idno><idno type="wicri:Area/Main/Curation">000F21</idno><idno type="wicri:Area/Main/Exploration">000F21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations</title><author wicri:is="90%"><name sortKey="Davies, Brian E" sort="Davies, Brian E" uniqKey="Davies B" first="Brian E." last="Davies">Brian E. Davies</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title><title level="j" type="issue">Oseltamivir (Tamiflu) and its use against seasonal, avian and pandemic strains of influenza</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date when="2010-04">2010</date><biblScope unit="vol">65</biblScope><biblScope unit="issue">suppl_2</biblScope><biblScope unit="page" from="ii5">ii5</biblScope><biblScope unit="page" to="ii10">ii10</biblScope></imprint><idno type="ISSN">0305-7453</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-7453</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children ≥1 year and adults of all ages may decrease the severity and duration of the symptoms of infection, while prophylactic dosing can prevent their onset. Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg twice daily. This predictable profile means that oseltamivir is suitable for use in diverse patient populations, which may include young children and elderly patients, various ethnic groups and those with renal or hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients with co-morbid conditions who are likely to be receiving concomitant medications.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Davies, Brian E" sort="Davies, Brian E" uniqKey="Davies B" first="Brian E." last="Davies">Brian E. Davies</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:81AE9C6C106E8206463503E64196239F7BDFA0B9
|texte= Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
}}
| This area was generated with Dilib version V0.6.33. |  |